Business
AngioDynamics is a medical technology company with Med Tech and Med Device product lines serving vascular, interventional, and related care markets.
AngioDynamics revenue fell 3.8% to $292.5M, the net loss narrowed sharply, and free cash flow improved but stayed negative.
The read at a glance✓ Audited against SEC data
- Business mix — Med Tech and Med Device productsNote
- Revenue — Revenue fell 3.8% to $292.5MWatch
- Profitability — Net loss narrowed 81.6%Note
- Cash — Free cash flow was -$14.6MWatch
- Balance sheet — Equity fell 11.0%Watch
- Insiders — 3 buys / 0 sells; cluster buyOK
- Accounting — Altman-Z distress; EQ safeWatch
Where the revenue comes from
Fiscal 2025, as ANGIODYNAMICS INC reports it. History and quarterly detail are in the app.
- Med Device$165.8M
- Med Tech$126.7M
Leadership changes
From ANGIODYNAMICS INC's own filings, the day they're filed.
- Wesley Johnson · director · departureeff. 2024-02-08
- Jan Stern Reed · director · departureeff. 2024-02-08
- Lorinda Burgess · director · appointment
Latest filings
- 8-K · Company announcement2026-04-23
- 10-Q · Quarterly report2026-04-02
- 8-K · Company announcement2026-04-02
- 8-K · Company announcement2026-02-03
- 8-K · Company announcement2026-01-14
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ANGIODYNAMICS INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.